Want to see TRDA full AI Analyst Report?
TRDA Stock Chart & Stats
$5.85
$0.23(3.93%)
At close: 4:00 PM EDT
$5.85
$0.23(3.93%)
Day’s Range― - ―
52-Week Range$5.02 - $16.45
Previous CloseN/A
Volume18.80K
Average Volume (3M)378.31K
Market Cap
$294.75M
Enterprise Value$136.29
Total Cash (Recent Filing)$223.00M
Total Debt (Recent Filing)$48.54M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 10, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.97
Shares Outstanding38,936,670
10 Day Avg. Volume453,749
30 Day Avg. Volume378,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)16.73
P/FCF Ratio-3.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.00Price Target Upside190.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.95
Revenue Forecast (FY)$10.51M
Bulls Say, Bears Say
Bulls Say
Solid Balance Sheet And RunwayEntradas's cash position (~$254.9M) and sizable assets provide a multi-quarter runway (stated funding into Q3 2027). This durable liquidity buffer reduces near-term refinancing pressure, allowing focus on clinical execution and multiple readouts without immediate reliance on dilutive capital.
Proprietary EEV Delivery PlatformThe EEV platform offers a structural competitive advantage by enabling intracellular delivery of peptides and proteins, an unmet technical capability. This foundational technology can expand program scope, attract partnerships, and support sustained pipeline growth across neuromuscular and retinal indications.
Positive Early Clinical Data And Program BreadthStatistically significant functional improvement and clean safety from ENTR-601-44 Cohort 1 materially de-risks the program and validates modality. Combined with multiple DMD and retinal programs and upcoming readouts, this durable scientific momentum supports long-term strategic value and partnering options.
Bears Say
High Cash Burn And Negative Cash FlowSustained operating and free cash outflows near ~$134M TTM reflect an intensive R&D spending profile. Over a multi-quarter horizon this burn rate raises refinancing risk and forces management to prioritize programs, potentially delaying or compressing development plans if additional non-dilutive funding is unavailable.
Low And Volatile Revenue BaseRevenue is currently immaterial and trending down, driven by lumpy collaboration receipts. With limited recurring operating revenue, the company remains heavily dependent on milestones and partners, leaving underlying commercial durability weak until later-stage approvals or sustained partnerships emerge.
Dependence On External Financing And Dilution RiskManagement signals reliance on equity-based tools to retain talent and fund operations. In the context of ongoing cash burn and limited revenue, expanded equity plans and probable future financings increase dilution risk and can constrain long-term shareholder returns absent material clinical or partnership milestones.
Entrada Therapeutics Inc News
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $5.02 and its highest was $16.45 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Entrada Therapeutics Inc’s market cap is $294.75M.
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 77 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on Aug 05, 2026. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.974 by -$0.036.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -1.01.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 38,936,670 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.974. Following the earnings report the stock price went down -2.486%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Currently, no hedge funds are holding shares in TRDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entrada Therapeutics Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (190.60% Upside)
$17.00 (190.60% Upside)
Blogger Sentiment
Bullish
TRDA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.3%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.40%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biotechnology company focused on developing therapies for diseases that require delivering biologic drugs into cells. The company’s core technology platform, referred to publicly as Endosomal Escape Vehicle (EEV), is designed to enable the intracellular delivery of therapeutic cargoes such as peptides and proteins. Entrada’s pipeline includes programs aimed at neuromuscular and other serious diseases, including a program for Duchenne muscular dystrophy (DMD).
TRDA Stock 12 Month Forecast
Average Price Target
$17.00
▲(190.60% Upside)
Technical Analysis
―
Black Diamond Therapeutics
―
C4 Therapeutics
―
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
34.73% Insiders
8.13% Mutual Funds
40.50% Other Institutional Investors
7.70% Public Companies and
Individual Investors